Acquired Antibodies to αIIbβ3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond

Transfusion Medicine Reviews

Volumn 32, Issue 3, 2018, Pages 155-164

  Nurden, Alan T ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

Glanzmann thrombasthenia; Isoantibodies to IIb 3; Platelet transfusion; Pregnancy, bone marrow transplants and gene therapy

Indexed keywords

ALPHA2BBETA3 INTEGRIN ANTIBODY; ANTIFIBRINOLYTIC AGENT; BETA3 INTEGRIN; FIBRIN; POLYCLONAL ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY PRODUCTION; BLEEDING; BLOOD TRANSFUSION; CONSENSUS DEVELOPMENT; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; EPISTAXIS; FETOPLACENTAL UNIT; FETUS CELL; FETUS RISK; FLOW CYTOMETRY; GENE THERAPY; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; GLANZMANN DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; LUNG EMBOLISM; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PREGNANCY; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN PROTEIN INTERACTION; REVIEW; RISK BENEFIT ANALYSIS; SKIN BLEEDING; THERAPY RESISTANCE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOSIS; TRANSPLANTATION CONDITIONING;

EID: 85048591921     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2018.05.002     Document Type: Review

References (100)

1. George, J.N., Caen, J.P., Nurden, A.T., Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75 (1990), 1383–1395.
2. Bellucci, S., Caen, J., Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev 16 (2002), 193–202.
3. Poon, M.-C., Di Minno, G., D'Oiron, R., Zotz, R., New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev 30 (2016), 92–99.
4. Coller, B.S., Shattil, S.A., The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112 (2008), 3011–3025.
5. Nurden, A.T., Fiore, M., Nurden, P., Pillois, X., Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118 (2011), 5996–6005.
6. Litinov, R.I., Farrell, D.H., Weisel, J.W., Bennett, J.S., The platelet integrin αIIbβ3 differentially interacts with fibrin versus fibrinogen. J Biol Chem 291 (2016), 7858–7867.
7. Nurden, A.T., Pillois, X., Fiore, M., Alessi, M.-C., Bonduel, M., Dreyfus, M., et al. Expanding the mutation spectrum of the αIIbβ3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat 36 (2015), 548–561.
8. Curtis, B.R., Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol 171 (2015), 671–682.
9. Audia, S., Mahévas, M., Samson, M., Godeau, B., Bonnette, B., Pathogenesis of immune thrombocytopenia. Autoimmun Rev 16 (2017), 620–632.
10. Cooper, N., State of the art—how I manage immune thrombocytopenia. Br J Haematol 177 (2017), 39–54.
11. Caen, J.P., Castaldi, P.A., Leclerc, J.C., Inceman, S., Larrieu, M.J., Probst, M., et al. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia (report of fifteen patients). Am J Med 41 (1966), 4–26.
12. Brown, C.H., Weisberg, R.J., Natelson, E.A., Alfrey, C.P. Jr., Glanzmann's thrombasthenia: assessment of the response to platelet transfusions. Transfusion 15 (1975), 124–131.
13. Degos, L., Dautigny, A., Brouet, J.C., Colombani, M., Ardaillou, N., Caen, J.P., et al. A molecular defect in thrombasthenic platelets. J Clin Invest 56 (1975), 236–240.
14. Coller, B.S., Peerschke, E.I., Seligsohn, U., Scudder, L.E., Nurden, A.T., Rosa, J.-P., Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor. J Lab Clin Med 107 (1986), 384–392.
15. Bierling, P., Fromont, P., Elbez, A., Duedari, N., Kieffer, N., Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sang 55 (1988), 109–113.
16. Tanning, E., Ursin, F., Knudsen, S., Thorsen, S., Jonsson, V., Immunization against platelet glycoprotein IIb-IIIa in Glanzmann's thrombasthenia. Eur J Haematol 58 (1997), 360–361.
17. Conte, R., Cirillo, D., Ricci, F., Tassi, C., Tazzari, P.L., Platelet transfusion in a patient affected by Glanzmann thrombasthenia with antibodies against GPIIb-IIIa. Haematologica 82 (1997), 73–74.
18. Levy-Toledano, S., Tobelem, G., Legrand, C., Bredoux, R., Degos, L., Nurden, A., et al. Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood 51 (1978), 1065–1071.
19. Hagen, I., Nurden, A., Bjerrum, O.J., Solum, N.O., Caen, J.P., Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome. J Clin Invest 65 (1980), 722–731.
20. Kunicki, T.J., Pidard, D., Rosa, J.P., Nurden, A.T., The formation of Ca2+-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood 58 (1981), 268–278.
21. Rosa, J.P., Kieffer, N., Didry, D., Pidard, D., Kunicki, T.J., Nurden, A.T., The human platelet membrane complex GPIIb-IIIa expresses antigenic sites not exposed on the dissociated glycoproteins. Blood 64 (1984), 1246–1253.
22. Lee, H., Nurden, A.T., Thomaidis, A., Caen, J.P., Relationship between fibrinogen binding and the platelet glycoprotein deficiencies in Glanzmann's thrombasthenia type I and type II. Br J Haematol 48 (1981), 47–57.
23. Hourdillé P., Benabdallah, S., Belloc, F., Nurden, A.T., Distribution of glycoprotein IIb-IIIa complexes in the surface membrane of human platelets and megakaryocytes. Br J Haematol 59 (1985), 171–182.
24. Newman, P.J., Seligsohn, U., Lyman, S., Coller, B.S., The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A 88 (1991), 3160–3164.
25. Nurden, A.T., Kunicki, T.J., Nurden, P., Fiore, M., Martins, N., Heilig, R., et al. Mutation analysis for a patient with Glanzmann thrombasthenia who produced a landmark iso-antibody to the αIIbβ3integrin. J Thromb Haemost 8 (2010), 1866–1868.
26. Jallu, V., Diaz-Ricart, M., Ordinas, A., Pico, M., Vezon, G., Nurden, A.T., Two human antibodies reacting with different epitopes on integrin β3 of platelets and endothelial cells. Eur J Biochem 222 (1994), 743–751.
27. Zhu, J., Zhu, J., Springer, T.A., Complete integrin headpiece opening in eight steps. J Cell Biol 201 (2013), 1053–1068.
28. Jacobin, M.J., Laroche-Traineau, J., Little, M., Keller, A., Peter, K.-H., Welschof, M., et al. Human IgG monoclonal antibody anti-αIIbβ3-binding fragments derived from immunized donors using phage display. J Immunol 168 (2002), 2035–2045.
29. Gruel, Y., Brojer, E., Nugent, D.J., Kunicki, T.J., Further characterization of the thrombasthenia-related idiotype OG. Antiidiotype defines a novel epitope(s) shared by fibrinogen Bβ chain, vitronectin, and von Willebrand factor and required for binding to β3. J Exp Med 180 (1994), 2259–2267.
30. Ishida, F., Gruel, Y., Brojer, E., Nugent, D.J., Kunicki, T.J., Repertoire cloning of a human IgG inhibitor of alphaIIbbeta3 function. The OG idiotype. Mol Immunol 32 (1995), 613–622.
31. Poon, M.C., D'Oiron, R., Von Depka, M., Khair, K., Négrier, C., Karafoulidou, A., et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2 (2004), 1096–1103.
32. Santoro, C., Rago, A., Biondo, F., Conti, L., Pulcinelli, F., Laurenti, L., et al. Prevalence of allo-immunization anti-HLA and anti-integrin αIIbβ3 in Glanzmann thrombasthenia patients. Haemophilia 16 (2010), 805–812.
33. Fiore, M., Firah, N., Pilloix, X., Nurden, P., Heilig, R., Nurden, A.T., Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 18 (2012), e201–e209.
34. Fiore, M., Pillois, X., Nurden, P., Nurden, A.T., Austerlitz, F., Founder effect and estimation of the age of the French gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur J Hum Genet 19 (2011), 981–987.
35. Ghosh, K., Kulkarni, B., Shetty, S., Nair, S., Antiplatelet antibodies in cases of Glanzmann's thrombasthenia with and without a history of multiple platelet transfusions. Indian J Hum Genet 15 (2009), 23–27.
36. Toogeh, G., Sharifian, R., Lak, M., Safaee, R., Artoni, A., Peyvandi, F., Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 77 (2004), 198–199.
37. Badlou, B.A., Yu, Y.P., Smid, W.M., Akkerman, J.-W.N., Platelet binding and phagocytosis by macrophages. Transfusion 46 (2006), 1432–1443.
38. Saris, A., Tomson, B., Brand, A., Mulder, A., Claas, F.H., Lorinser, J., et al. Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization. Blood 131 (2018), 144–152.
39. Martin, I., Kriaa, F., Proulle, V., Guillet, B., Kaplan, C., D'Oiron, R., et al. Protein A Sepharose immunadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 119 (2002), 991–997.
40. Al-Battat, S., Rand, M.L., Bouskill, V., Lau, W., Blanchette, V.S., Kahr, W.H.A., et al. Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions. Br J Haematol 181 (2017), 410–413.
41. Nurden, A., Combrié R., Nurden, P., Detection of transfused platelets in a patient with Glanzmann thrombasthenia. Thromb Haemost 87 (2002), 543–544.
42. Male, C., Koren, D., Eichelberger, B., Kaufmann, K., Panzer, S., Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thromboelastography. Vox Sang 91 (2006), 174–177.
43. Li, Z., Nardi, M.A., Wu, J., Pan, R., Zhang, W., Karpatkin, S., Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin. J Biol Chem 283 (2008), 3224–3230.
44. Orsini, S., Noris, P., Bury, L., Heller, P.G., Santoro, C., Kadir, R.A., et al. Haematologica 102 (2017), 1192–1203.
45. Tengborn, L., Petruson, B., A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 75 (1996), 981–982.
46. Poon, M.-C., Derners, C., Jobin, F., Wu, J.W.Y., Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94 (1999), 3951–3953.
47. Almeida, A.M., Khair, K., Hann, I., Liesner, R., The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 121 (2003), 477–481.
48. Di Minno, G., Zotz, R.B., D'Oiron, R., Bindslev, N., Di Minno, M.N., Poon, M.C., The international prospective Glanzmann thrombasthenia registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. Haematologica 100 (2015), 1031–1037.
49. Poon, M.C., D'Oiron, R., Zotz, R.B., Bindslev, N., Di Minno, M.N., Di Minno, G., The international prospective Glanzmann thrombasthenia registry: treatment and outcomes in surgical intervention. Haematologica 100:8 (2015), 1038–1044.
50. Recht, M., Rajpurkar, M., Chitlur, M., D'Oiron, R., Zotz, R., Di Minno, G., et al. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. Am J Hematol 92 (2017), 646–652.
51. Monroe, D.M., Hoffman, M., Oliver, J.A., Roberts, H.R., Hedner, U., Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 114 (1997), 114–120.
52. Ménart, C., Trzeciak, M.C., Attali, O., Négrier, C., Continuous infusion of NovoSeven® during colectomy in a Glanzmann thrombasthenia patient with anti-glycoprotein IIb-IIIa antibody. Haemophilia, 4, 1998, 299 [abstr].
53. D'Oiron, R., Menart, C., Trzeciak, M.C., Nurden, P., Fressinaud, E., Dreyfus, M., et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 83 (2000), 644–647.
54. Nurden, A.T., Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses. Blood Rev 31 (2017), 287–299.
55. Lisman, T., Moschatsis, S., Adelmeier, J., Nieuwenhuis, H.K., De Groot, P.G., Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 101 (2003), 1864–1870.
56. Lisman, T., de Groot, P.G., The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. Blood Rev 29 (2015), 223–229.
57. Schut, A.M., Kirschbaum, M., Adelmeijer, J., de Groot, P.G., Lisman, T., In vitro uptake of recombinant factor VIIa by megakaryocytes with subsequent production of platelets containing functionally active drug. Br J Haematol 178 (2017), 482–486.
58. Soslau, G., Class, R., Morgan, D.A., Foster, C., Lord, S.T., Marchese, P., et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 276 (2001), 21173–21183.
59. Alshehri, O.M., Hughes, C.E., Montague, S., Watson, S.K., Frampton, J., Bender, M., et al. Fibrin activates GPVI in human and mouse platelets. Blood 126 (2015), 1601–1608.
60. Dargaud, Y., Bordet, J.-C., Treciak, M.C., Vinciguerra, C., Negrier, C., A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica, 91(6 Suppl), 2006, ECR20.
61. Lak, M., Scharling, B., Blemings, A., Sharifian, R., Maleki, Z., Daree, A., et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Hemophilia 14 (2008), 103–110.
62. Kashiwagi, H., Kiyomizu, K., Kamae, T., Nakazawa, T., Tadokoro, S., Takkiguchi, S., et al. Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-αIIbβ3 alloantibodies. Int J Hematol 93 (2011), 106–111.
63. Buyukasik, Y., Boyraz, G., Selcuk, I., Bektas, O., Tuncer, Z.S., Giant abdominopelvic haematoma arising from ovulation in Glanzmann's thrombasthenia patient with platelet refractoriness: treatment with surgery and intra-abdominal transexamic acid. Acta Haematol 128 (2012), 154–157.
64. Duarte, B.K.L., De Souza, S.M., Costa-Lima, C., Medina, S.S., Ozelo, M.C., Thalidomide for the treatment of gastrointestinal bleeding in a patient with Glanzmann's thrombasthenia. Hematol Rep, 9(2), 2017, 6961, 10.4081/hr.2017.6961 [eCollection 2017].
65. Siddiq, S., Clark, A., Mumford, A., A systematic review of the management and outcomes of pregnancy in Glanzmann's thrombsthenia. Haemophilia 17 (2011), e858–e869.
66. Civaschi, E., Klersy, C., Melazzini, F., Pujol-Moix, N., Santoro, C., Cattaneo, M., et al. Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders. Br J Haematol 170 (2015), 559–563.
67. Vivier, M., Treisser, A., Naett, M., Diemunsch, P., Schmitt, J.P., Waller, C., et al. Glanzmanns thrombasthenia and pregnancy. Contribution of plasma exchange before scheduled cesarean section. J Gynecol Obstet Biol Reprod (Paris) 18 (1989), 507–513.
68. Ito, K., Yoshida, H., Hatoyama, H., Matsumoto, H., Ban, C., Mori, T., et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang 61 (1991), 40–46.
69. Kashyap, R., Kriplani, A., Saxena, R., Takkar, D., Choudhry, V.P., Pregnancy in a patient of Glanzmann thrombasthenia with antiplatelet antibodies. J Obstet Gynecol Res 23 (1997), 247–250.
70. Léticée, N., Kaplan, C., Lémory, D., Pregnancy in mother with Glanzmann's thrombasthenia and iso-antibody against GPIIb-IIIa: is there a foetal risk?. Eur J Obstet Gynecol Reprod Biol 121 (2005), 139–142.
71. Wijemanne, A., Watte-Coote, I., Austin, S., Glanzmann thrombasthenia in pregnancy: optimizing maternal and fetal outcomes. Obstet Med 9 (2016), 169–170.
72. Kabir-Salmani, M., Shiokawa, S., Akimoto, Y., Sakai, K., Nagamatsu, S., Sakai, K., et al. Alphavbeta3 integrin signaling pathway is involved in insulin-like growth factor I-stimulated human extravillous trophoblast cell migration. Endocrinology 144 (2003), 1620–1630.
73. Yougbaré I., Tai, W.-S., Zdravic, D., Oswald, B.E., Lang, S., Zhu, G., et al. Activated NK cells cause placental dysfunction and miscarriages in fetal alloimmune thrombocytopenia. Nat Commun, 8(1), 2017, 224, 10.1038/s41467-017-00269-1.
74. Yougbaré I., Lang, S., Yang, H., Chen, P., Zhao, X., Tai, W.-S., et al. Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 125 (2015), 1545–1556.
75. Santoso, S., Wihadmadyatami, H., Bakchoul, T., Werth, S., Al-Fakhri, N., Bein, G., et al. Antiendothelial αvβ3 antibodies are a major cause of intracranial bleeding in fetal/neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol 36 (2016), 1517–1524.
76. Wihadmadyatami, H., Roder, L., Berghofer, H., Bein, G., Heidinger, K., Sachs, U.J., et al. Immunisation against αIIbβ3 and αvβ3 in a type I variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on β3. Thromb Haemost 116 (2016), 262–271.
77. Bellucci, S., Devergie, A., Gluckman, E., Tobelem, G., Lethielleux, P., Benbunan, M., et al. Complete correction of Glanzmann's thrombasthenia by allogeneic bone-marrow transplantation. Br J Haematol 59 (1985), 635–641.
78. Bellucci, S., Damaj, G., Boval, B., Rocha, V., Devergie, A., Yacoub-Agha, Y., et al. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant 35 (2000), 327–330.
79. Johnson, A., Goodall, A.H., Downie, C.J., Vellodie, A., Michael, D.P., Bone marrow transplantation for Glanzmann's thrombasthenia. Bone Marrow Transplant 14 (1994), 147–150.
80. McColl, M.D., Gibson, B.E.S., Sibling allogeneic bone marrow transplantation for Glanzmann thrombasthenia. Br J Haematol 99 (1997), 58–60.
81. Flood, V.H., Johnson, F.L., Boshkov, L.K., Thomas, G.A., Nugent, D.J., Bakke, A.C., et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer 45 (2005), 971–975.
82. French, D.L., Fruchtman, S., Mitchell, W.B., Coller, B.S., Peretz, H., Evidence for megakaryocyte engraftment following reduced-intensity conditioning. Exp Hematol 32 (2004), 877–880.
83. Connor, P., Khair, K., Liesner, R., Amrolia, P., Veys, P., Ancliff, P., et al. Stem cell transplantation for children with Glanzmann thrombasthenia. Br J Haematol 140 (2008), 566–571.
84. Ishaqi, M.K., El-Hayek, M., Gassas, A., Khanani, M., Trad, O., Baroudi, M., et al. Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr Blood Cancer 52 (2009), 682–683.
85. Miller, W., Dunn, A., Chiang, K.Y., Sustained engraftment and resolution of bleeding phenotype after unrelated cord blood hematopoietic stem cell transplantation for severe Glanzmann thrombasthenia. Pediatr Hematol Oncol 31 (2009), 437–439.
86. Kitko, C.L., Levine, J.E., Matthews, D.C., Carpentier, P.A., Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia. Pediatr Transplant 15 (2011), e42–e46.
87. Wiegering, V., Winkler, B., Langhammer, F., Wölfl, M., Wirbelauer, J., Sauer, K., Kobsar, A., Meyer, T., Strauss, A., Bakchoul, T., Eyrich, M., Schlegel, P.G., Allogeneic hematopoietic stem cell transplantation in Glanzmann thrombasthenia complicated by platelet alloimmunization. Klin Padiatr 223 (2011), 173–175.
88. Sullivan, S.K., Mills, J.A., Koukouritaki, S.B., Vo, K.K., Lyde, R.B., Paluru, P., et al. High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood 123 (2014), 753–757.
89. Hu, L., Du, L., Zhao, Y., Li, W., Ouyang, Q., Zhou, D.I., et al. Modeling Glanzmann thrombasthenia using patient specific iPSCs and restoring platelet aggregation function by CD41 overexpression. Stem Cell Res 20 (2017), 14–20.
90. Seligsohn, U., Mibashan, R.S., Rodeck, C.H., Nicolaides, K.H., Millar, D.S., Coller, B.S., Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet, 2(8469–70), 1985, 1419.
91. Nectoux, J., Current, emerging and future applications of digital PCR in non-invasive prenatal diagnosis. Mol Diagn Ther 22 (2017), 139–148.
92. Wilcox, D.A., White, G.C. II, Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J Thromb Haemost 1 (2003), 2300–2311.
93. Wilcox, D.A., Olsen, J.C., Bray, P.F., French, D.L., Steeber, D.A., Bell, W.R., et al. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood 95 (2000), 3645–3651.
94. Fang, J., Hodivala-Dilke, K., Johnson, B.D., Du, L.M., Hynes, R.O., White, G.C. II, et al. Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia. Blood 106 (2005), 2671–2679.
95. Fang, J., Jensen, E.S., Boudreaux, M.K., Du, L.M., Hawkins, T.B., Koukouritaki, S.B., et al. Platelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogs. Proc Natl Acad Sci 108 (2011), 9583–9588.
96. Zhang, N., Zhi, H., Curtis, B.R., Rao, S., Jobaliya, C., Poncz, M., et al. CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes. Blood 127 (2016), 675–680.
97. George, L.A., Sullivan, S.K., Giermasz, A., Rasko, J.E.J., Samuelson-Jones, B.J., Ducore, J., et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 377 (2017), 2215–2227.
98. Slichter, S.J., Pellham, E., Bailey, S.L., Christoffel, T., Gettinger, I., Gaur, L., et al. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model. Blood 130:8 (2017), 1052–1061.
99. Gorski, M.M., Blighe, K., Lotta, L.A., Pappalardo, E., Garagiola, I., Mancini, I., et al. Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. Blood 127:23 (2016), 2924–2933.
100. Metzner, K., Bauer, J., Ponzi, H., Ulrich, A., Curtis, B.R., Detection and identification of platelet antibodies using a sensitive multiplex assay system-platelet antibody bead array. Transfusion 57:7 (2017), 1724–1733.